Coronary atherosclerotic heart disease
Conditions
Interventions
Intensive Group:Tolelsimab 150mg QOW + Rosuvastatin 10mg QN ± Ezetimibe 10mg QD
Control Group:Rosuvastatin 10mg QN ± Ezetimibe 10mg QD
Sponsors
The Second Hospital of Tianjin Medical University
Eligibility
Sex/Gender
All
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: 1.18 years 2.8 mmol/L for statin-naïve patients, or LDL-C > 1.8 mmol/L for patients already on statin therapy; 5.Ability to comply with 6-month follow-up.
Exclusion criteria
Exclusion criteria: 1.Patients requiring emergency CABG surgery where baseline imaging data cannot be obtained. 2.Hemodynamic instability or uncontrolled malignant arrhythmia. 3.Complicated by cardiogenic shock or mechanical complications of the heart. 4.Treatment with any PCSK9 inhibitor within the past 3 months. 5.Severe renal insufficiency (creatinine clearance <30 mL/min), active liver disease or hepatic insufficiency, hematological diseases, metabolic or endocrine dysfunction, systemic infection, active malignant tumors, or any other life-threatening condition, or an expected survival of <1 year. 6.Concurrent acute or chronic pericardial disease. 7.Pregnant or breastfeeding women, or women planning pregnancy. 8.Patients deemed ineligible for enrollment by the investigator.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| EAT volume and density;Coronary atherosclerotic plaque volume; | — |
Secondary
| Measure | Time frame |
|---|---|
| Graft patency rate;Blood lipids;Serum adipokines;Inflammatory cytokines; | — |
Countries
China
Contacts
Public ContactChen tienan
The Second Hospital of Tianjin Medical University
Outcome results
None listed